TTI - TETRA Technologies, Inc.
SPRING, Texas, Sept. 30, 2026 /PRNewswire/ -- TETRA Technologies, Inc. (NYSE: TTI) will release Third Quarter 2026 results after the market closes on November 2, 2026 and will host a conference call to discuss the results and outlook on November 3, 2026, at 10:00am ET.
Valaris (NYSE: VAL - Get Free Report) and Tetra Technologies (NYSE: TTI - Get Free Report) are both energy companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings. Profitability This table compares Valaris and Tetra Technologies' net
MIND Technology (NASDAQ: MIND - Get Free Report) and Tetra Technologies (NYSE: TTI - Get Free Report) are both small-cap energy companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations. Insider and Institutional Ownership 9.8% of MIND
San Diego, California--(Newsfile Corp. - September 21, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric diseases, today announced the results of its Annual and Special Meeting of Shareholders ("Meeting") held on September 8, 2026, and provided a corporate update highlighting recent clinical, regulatory, and financial milestones. Meeting Results All items of business put before shareholders at the Meeting were approved by the requisite majority of votes cast.
Tetra Technologies is an interesting investment opportunity, given the sizable share price pullback and its potential for growth in the next few years. TTI's innovations and services are poised for increased demand as the industry tackles harder-to-recover reserves and aging fields. Despite 8% revenue growth in Q2, net income declined 10%, but interest expense remains comfortably low at 1.8% of revenues.
San Diego, California--(Newsfile Corp. - September 3, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing sulfur-based therapeutics for rare diseases, today announced that it has engaged Brisco Capital Partners Corp. ("Brisco") to provide investor relations services. Brisco will assist the Company in expanding communications with shareholders, investors and the broader investment community to increase awareness of Thiogenesis and its development programs.
SPRING, Texas, Sept. 2, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) announced that Brady Murphy, Chief Executive Officer, and Kurt Hallead, Treasurer and VP of Investor Relations, will be meeting with institutional investors at the following conferences: September 9, 2026: Barclays 40th Annual Energy-Power Conference (NY, NY) September 10, 2026: Jefferies Renewables, Clean Energy and E&C Conference (NY, NY) TETRA's most recent presentation is available on its Investor Relations site.
Technip Energies (OTCMKTS:THNPY - Get Free Report) and Tetra Technologies (NYSE: TTI - Get Free Report) are both energy companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk. Valuation and Earnings This table compares Technip Energies
Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis Transcript
Tetra Technologies NYSE: TTI reported second-quarter revenue of $185.7 million, up 19% sequentially and 7% from the prior-year period, as strength in international and offshore operations offset delayed Middle East fluid shipments tied to regional conflict.
Although the revenue and EPS for Tetra Technologies (TTI) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
TETRA Technologies, Inc. (TTI) Q2 2026 Earnings Call Transcript
Tetra Technologies (TTI) came out with quarterly earnings of $0.08 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.09 per share a year ago.
Although the revenue and EPS for Tetra Technologies (TTI) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
SPRING, Texas, Aug. 3, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) announced financial results for the three and six months ended June 30, 2026. Second-Quarter 2026 Financial Highlights Revenues of $185.7 million Income from continuing operations of $10.2 million, inclusive of $1.1 million of unusual charges Adjusted EBITDA of $31.9 million Net Income per share from continuing operations of $0.07, adjusted net income per share of $0.08 Launched TETRA Neptune Z-Lite, awarded a three-well Gulf of America Deepwater Project Raised $108 million of net proceeds related to the equity offering Board of Directors approved final investment decision ("FID") for the Arkansas Bromine Project Brady Murphy, TETRA's President and Chief Executive Officer, stated, "We delivered one of our strongest second-quarter and first-half financial performances in the past decade, reflecting the strength of our base business and our ability to grow in deepwater and international markets.
STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling
Tetra Technologies (TTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SPRING, Texas, July 13, 2026 /PRNewswire/ -- TETRA Technologies, Inc. (NYSE:TTI) will release Second Quarter 2026 results after the market closes on August 3, 2026 and will host a conference call to discuss the results and outlook on August 4, 2026, at 10:30am ET. CLICK HERE to pre-register and obtain your dial in number and passcode.
San Diego, California--(Newsfile Corp. - July 13, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing novel sulfur-based thiol therapies for rare pediatric, metabolic and mitochondrial disorders, today announced that the U.S. Food and Drug Administration ("FDA") has granted Rare Pediatric Disease ("RPD") designation to its lead candidate, TTI-0102, for the treatment of Leigh syndrome. The FDA grants RPD designation to therapies intended to treat serious or life-threatening diseases that primarily affect children from birth through 18 years of age.
Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript